Jazz Pharma Posts 12% Increase in Q4 Profit, But Still Misses; Guides Above the Street

Jazz Pharmaceuticals (NASDAQ: JAZZ ) reported fourth quarter 2013 results, missing both earnings per share and revenue analyst estimates. Shares are down 7 percent to $162.70 following the report. The company reported revenue of $235.8 million versus the Street estimate of $238.1 million. Earnings per share of $1.72 missed the